Gland Pharma Ltd
GLANDGland Pharma Ltd
GLAND


Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
34.53 | 2.79 | 1.35% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
48.59 | 6.21 | 0.55% |
Forecast & Ratings
Detailed Forecast from 10 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Gland Pharma is engaged in manufacturing small volume parenterals (SVPs) and contract development services.
Peers
Compare with peersGet more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 2,772.41 | 3,597.66 | 4,624.65 | 3,865.06 | 5,834.96 | 5,940.78 | ||||||
Raw Materials | 1,108.93 | 1,765.36 | 2,072.53 | 1,732.34 | 2,045.20 | 4,448.99 | ||||||
Power & Fuel Cost | 78.50 | 74.59 | 95.05 | 124.84 | 229.99 | |||||||
Employee Cost | 277.66 | 311.36 | 338.57 | 403.26 | 1,256.89 | |||||||
Selling & Administrative Expenses | 98.54 | 128.48 | 177.92 | 187.93 | 286.86 | |||||||
Operating & Other expenses | 114.15 | -119.14 | 206.49 | 207.92 | 512.71 | |||||||
EBITDA | 1,094.63 | 1,437.01 | 1,734.09 | 1,208.77 | 1,503.31 | 1,491.79 | ||||||
Depreciation/Amortization | 94.59 | 98.78 | 110.30 | 146.74 | 344.57 | 374.73 | ||||||
PBIT | 1,000.04 | 1,338.23 | 1,623.79 | 1,062.03 | 1,158.74 | 1,117.06 | ||||||
Interest & Other Items | 7.18 | 3.41 | 5.24 | 7.45 | 26.20 | 44.51 | ||||||
PBT | 992.86 | 1,334.82 | 1,618.55 | 1,054.58 | 1,132.54 | 1,072.55 | ||||||
Taxes & Other Items | 220.01 | 337.85 | 406.89 | 273.54 | 360.08 | 368.14 | ||||||
Net Income | 772.85 | 996.97 | 1,211.66 | 781.04 | 772.46 | 704.41 | ||||||
EPS | 49.88 | 62.60 | 73.91 | 47.48 | 46.90 | 42.77 | ||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | 20.00 | 20.00 | ||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.47 |
Company Updates
Annual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Gland Pharma Ltd | 31.48 | 2.79 | 1.35% |
Sun Pharmaceutical Industries Ltd | 43.75 | 6.24 | 0.77% |
Cipla Ltd | 28.85 | 4.44 | 0.88% |
Torrent Pharmaceuticals Ltd | 62.82 | 15.18 | 0.91% |
Price Comparison
Compare GLAND with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Gland Pharma Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.4808% | Percentage of the fund’s portfolio invested in the stock 1.15% | Change in the portfolio weight of the stock over the last 3 months -0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 59/84 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.3118% | Percentage of the fund’s portfolio invested in the stock 1.54% | Change in the portfolio weight of the stock over the last 3 months -0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 13/111 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.8182% | Percentage of the fund’s portfolio invested in the stock 1.54% | Change in the portfolio weight of the stock over the last 3 months -0.18% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 50/85 (-1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 16, 2024
Dividend/Share
₹20.00
Ex DateEx Date
Aug 16, 2024
Net profit of Gland Pharma rose 6.69% to Rs 204.69 crore in the quarter ended December 2024 as against Rs 191.86 crore during the previous quarter ended December 2023. Sales declined 10.43% to Rs 1384.05 crore in the quarter ended December 2024 as against Rs 1545.16 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1384.051545.16 -10 OPM %26.0123.06 - PBDT395.63388.50 2 PBT299.30283.16 6 NP204.69191.86 7 Powered by Capital Market - Live
Profit before tax (PBT) stood at Rs 299.30 crore in Q3 FY25, up 5.68%, compared with Rs 283.20 crore in the third quarter of FY24. For Q3 of FY25, EBITDA was Rs 360 crore, registering a growth of 1.20% YoY. EBITDA margin improved from 23% to 26% during the quarter. Revenue from the US market stood at Rs 729.30 crore (down 11.23% YoY), revenue from Europe was at Rs 264.60 crore (down 18.60% YoY), Canada, Australia, and New Zealand stood at Rs 45.90 crore (up 20.15% YoY), while revenue from India was at Rs 56.20 crore and the rest of the world was at Rs 288.10 crore during the period under review. Total capex incurred during the quarter was Rs 137.90 crore. R&D expenses stood at Rs 43.70 crore in Q2 of FY25 (4.3% of revenue). Cenexi's gross profit shed 14.25% YoY to Rs 285.60 crore, and revenue from operations decreased 16.26% YoY to Rs 371.70 crore during the quarter. During the quarter, the company launched 13 new molecules, including chlorpromazine, dexamethasone, phenylephrine, phytonadione, and diphenhydramine. Additionally, the company received Establishment Inspection Reports (EIRs) from the USFDA for its Dundigal and Pashamylaram facilities in Hyderabad, India, marking the successful closure of recent USFDA inspections. On outlook front, the company said Cenexi maintains its goal of achieving a positive EBITDA for the next fiscal year, driven by an increase in revenue above the '200 million threshold. Srinivas Sadu, Executive Chairman of Gland Pharma, said, 'Our Q3 FY25 revenue was at Rs 13,841 million with an EBITDA of Rs 3,600 million, resulting in a 26% EBITDA margin. Notably, our base business EBITDA margin saw a significant improvement of 500 basis points, reaching 39%. We are also excited about the progress of our strategic biologics CDMO collaborations with some of the leading companies in this space. These partnerships open doors to exciting opportunities in the rapidly growing biologics CDMO segment and are expected to generate incremental revenue starting next financial year. Furthermore, the recent conclusion of the USFDA inspections at our Dundigal and Pashamylaram facilities underscores our unwavering commitment to quality and regulatory compliance. We remain focused on driving long-term value creation through strategic partnerships, innovation, and continued investments in new products and technologies.' Shyamakant Giri, CFO, Gland Pharma, said, 'I am honored and excited to lead Gland Pharma as its new CEO. Building on the company's strong foundation, my focus will be on enhancing operational excellence in our base business, ensuring Cenexi's successful turnaround, identifying and pursuing new growth opportunities, and further solidifying our position as a leader in the CDMO space, particularly in biologics and complex injectables. I believe that by fostering a culture of innovation, collaboration, and customercentricity, we can achieve sustainable growth and create long-term value for all our stakeholders.' Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. Shares of Gland Pharma slipped 5.41% to currently trade at Rs 1,438 on the BSE.Powered by Capital Market - Live
Gland Pharma announced that following the Inspection for Good Manufacturing Practices (GMP) by US FDA at the Company's Pashamylaram Facility at Hyderabad between 25 July, 2024 and 02 August, 2024; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.Powered by Capital Market - Live
The Pashamylaram facility received an EIR, which indicates closure of the inspection, Gland Pharma said in a filing. The USFDA inspected the facility between 25 July 2024 and 2 August 2024 for good manufacturing practices (GMP) and issued three Form 483 observations. These observations were procedural in nature. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. On a consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. The scrip rose 0.10% to settle at Rs 1,678.95 on Friday, 18 January 2025. Powered by Capital Market - Live
Gland Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1699.55, up 1.41% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.43% on the day, quoting at 23211.05. The Sensex is at 76656.14, down 0.5%. Gland Pharma Ltd has slipped around 3.65% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has slipped around 1.43% in last one month and is currently quoting at 21909.75, up 0.39% on the day. The volume in the stock stood at 62727 shares today, compared to the daily average of 2.35 lakh shares in last one month.The PE of the stock is 25.06 based on TTM earnings ending September 24.Powered by Capital Market - Live
Gland Pharma will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live
The United States Food and Drug Administration (USFDA) conducted a surprise inspection of the company's Dundigal Facility for good manufacturing practices (GMP) between 22 July 2024 and 25 July 2024. Earlier, on 25 July, the durg maker stated that the inspection was concluded with 2 483 observations. These observations were procedural in nature and also were neither repeated observations nor related to data integrity. Now, the company has received an EIR from the USFDA stating closure of the inspection. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. On a consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. The scrip rose 0.24% to currently trade at Rs 1,676.75 on the BSE.Powered by Capital Market - Live
Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1785, down 2.46% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.02% on the day, quoting at 23521.8. The Sensex is at 77676.23, up 0.07%.Gland Pharma Ltd has gained around 0.55% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 0.59% in last one month and is currently quoting at 22868.1, down 1.9% on the day. The volume in the stock stood at 3.11 lakh shares today, compared to the daily average of 2.26 lakh shares in last one month.The PE of the stock is 27.3 based on TTM earnings ending September 24.Powered by Capital Market - Live
Gland Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1900.05, up 3.15% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.45% on the day, quoting at 24079.19921875. The Sensex is at 79453, down 0.61%. Gland Pharma Ltd has added around 5.51% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has added around 3.86% in last one month and is currently quoting at 23553.4, down 1.12% on the day. The volume in the stock stood at 3.67 lakh shares today, compared to the daily average of 1.73 lakh shares in last one month.The PE of the stock is 27.52 based on TTM earnings ending September 24.Powered by Capital Market - Live
In a regulatory filing made yesterday, the company stated that the Agence nationale de s'curit' du m'dicament et des produits de sant' (ANSM), France, conducted a good manufacturing practices (GMP) inspection of Cenexi's Fontenay manufacturing facility (material subsidiary of Gland Pharma) between 9 to 19 of December 2024. The said inspection was concluded, and the facility received an official notification on 24 December 2024, citing ten observations. Cenexi is committed to working closely with the ANSM to address the observations,' Gland Pharma stated. Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. On a consolidated basis, the firm's net profit declined 15.74% to Rs 163.53 crore despite a 2.36% increase in revenue from operations to Rs 1,405.83 crore in Q2 FY25 over Q2 FY24. The scrip was up 0.62% to currently trade at Rs 1791 on the BSE. Powered by Capital Market - Live
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant